裸盖菇素减少雄性大鼠海洛因寻求行为并调节伏隔核与前额叶皮层炎症基因表达
临床前与人类研究提示裸盖菇素可能减少持续性适应不良行为,但阿片领域缺乏此类研究。本研究在大鼠海洛因自我给药模型中系统给予裸盖菇素或5-HT2AR拮抗剂,发现单次3.0 mg/kg裸盖菇素在复发测试前4-24小时给药可减弱线索诱发的海洛因寻求,而5-HT2AR拮抗剂加剧复发;前额叶皮层RNA测序显示裸盖菇素调节细胞骨架与细胞因子信号基因,选择性抑制前额叶IL-17a足以减少海洛因复发。
要点
- 单次3.0 mg/kg裸盖菇素在复发测试前4-24小时给药减弱线索诱发的海洛因寻求,但不改变海洛因摄取。
- 5-HT2AR拮抗剂酮色林和volinanserin加剧海洛因复发。
- 前额叶IL-17a信号可能是裸盖菇素减少海洛因寻求的下游通路。
核心结论
- 裸盖菇素减少海洛因复发,并突出IL-17a信号作为裸盖菇素减少海洛因寻求的潜在下游通路。
研究设计与样本
- 在大鼠海洛因自我给药模型中,系统给予裸盖菇素或5-HT2AR拮抗剂酮色林和volinanserin,评估对海洛因摄取及强制戒断后复发的影响。
- 另用未接触药物的大鼠给予裸盖菇素和/或酮色林,24小时后采集前额叶皮层组织进行RNA测序。
- 对显示裸盖菇素介导的海洛因寻求抑制的动物,用基因表达阵列测量前额叶皮层趋化因子/细胞因子分子。
主要发现
- 裸盖菇素不改变海洛因摄取,但复发测试前4-24小时单次暴露于3.0 mg/kg裸盖菇素减弱线索诱发的海洛因寻求。
- 5-HT2AR拮抗剂加剧海洛因复发。
- 3.0 mg/kg裸盖菇素在前额叶皮层调节的基因数约为1.0 mg/kg的2倍,包括细胞骨架和细胞因子信号相关基因。
- 酮色林阻断超过90%的裸盖菇素调节基因,包括IL-17a细胞因子受体Il17ra。
- 裸盖菇素调节4个基因包括Il17a,部分基因与复发行为相关;选择性抑制前额叶IL-17a足以减少海洛因复发。
关键数值与推荐
- 海洛因自我给药剂量为0.075 mg/kg/次输注。
- 裸盖菇素剂量为3.0 mg/kg和1.0 mg/kg。
- 复发测试前4-24小时给予3.0 mg/kg裸盖菇素。
- 酮色林阻断超过90%的裸盖菇素调节基因。
- 3.0 mg/kg裸盖菇素在前额叶皮层调节的基因数约为1.0 mg/kg的2倍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical and human studies indicate psilocybin may reduce perseverant maladaptive behaviors, including nicotine and alcohol seeking. Such studies in the opioid field are lacking, though opioids are involved in >50% of overdose deaths. Psilocybin is an agonist at the serotonin 2A receptor (5-HT2AR), a well-documented target for modulation of drug seeking, and evidence suggests 5-HT2AR agonists may dampen motivation for opioids. We sought to investigate the therapeutic efficacy of psilocybin in mediating cessation of opioid use and maintenance of long-lasting abstinence from opioid seeking behavior in a rat model of heroin self-administration (SA). Psilocybin or 5-HT2AR antagonists ketanserin and volinanserin were administered systemically to rats prior to SA of 0.075 mg/kg/infusion of heroin, or relapse following forced abstinence. Psilocybin did not alter heroin taking, but a single exposure to 3.0 mg/kg psilocybin 4-24 h prior to a relapse test blunted cue-induced heroin seeking. Conversely, 5-HT2AR antagonists exacerbated heroin relapse. To begin to elucidate mechanisms of psilocybin, drug-naïve rats received psilocybin and/or ketanserin, and tissue was collected from the prefrontal cortex (PFC), a region critical for drug seeking and responsive to psilocybin, 24 h later for RNA-sequencing. 3.0 mg/kg psilocybin regulated ~2-fold more genes in the PFC than 1.0 mg/kg, including genes involved in the cytoskeleton and cytokine signaling. Ketanserin blocked >90% of psilocybin-regulated genes, including the IL-17a cytokine receptor, Il17ra. Psychedelic compounds have reported anti-inflammatory properties, and therefore we performed a gene expression array to measure chemokine/cytokine molecules in the PFC of animals that displayed psilocybin-mediated inhibition of heroin seeking. Psilocybin regulated 4 genes, including Il17a, and a subset of genes correlated with relapse behavior. Selective inhibition of PFC IL-17a was sufficient to reduce heroin relapse. We conclude that psilocybin reduces heroin relapse and highlight IL-17a signaling as a potential downstream pathway of psilocybin that also reduces heroin seeking.
引用
- Floris G, Dabrowski KR, Zanda MT, et al. Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats. Mol Psychiatry. 2024. PMID: 39433903. doi:10.1038/s41380-024-02788-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。